Background Rimonabant, a selective cannabinoid-1 receptor (CB1)blocker, has been shown to reduce body weight and improve cardiovascularrisk factors in obese patients. The Rimonabant in Obesity–Lipids(RIO-Lipids) study examined the effects of rimonabant on metabolicrisk factors, including adiponectin levels, in high-risk patientswho are overweight or obese and have dyslipidemia.
Methods We randomly assigned 1036 overweight or obese patients(body-mass index [the weight in kilograms divided by the squareof the height in meters], 27 to 40) with untreated dyslipidemia(triglyceride levels >1.69 to 7.90 mmol per liter, or a ratioof cholesterol to high-density lipoprotein [HDL] cholesterolof >4.5 among women and >5 among men) to double-blindedtherapy with either placebo or rimonabant at a dose of 5 mgor 20 mg daily for 12 months in addition to a hypocaloric diet.
Results The rates of completion of the study were 62.6 percent,60.3 percent, and 63.9 percent in the placebo group, the groupreceiving 5 mg of rimonabant, and the group receiving 20 mgof rimonabant, respectively. The most frequent adverse eventsresulting in discontinuation of the drug were depression, anxiety,and nausea. As compared with placebo, rimonabant at a dose of20 mg was associated with a significant (P<0.001) mean weightloss (repeated-measures method, –6.7±0.5 kg, andlast-observation-carried-forward analyses, –5.4±0.4kg), reduction in waist circumference (repeated-measures method,–5.8±0.5 cm, and last-observation-carried-forwardanalyses, –4.7±0.5 cm), increase in HDL cholesterol(repeated-measures method, +10.0±1.6 percent, and last-observation-carried-forwardanalyses, +8.1±1.5 percent), and reduction in triglycerides(repeated-measures method, –13.0±3.5 percent, andlast-observation-carried-forward analyses, –12.4±3.2percent). Rimonabant at a dose of 20 mg also resulted in anincrease in plasma adiponectin levels (repeated-measures method,57.7 percent, and last-observation-carried-forward analyses,46.2 percent; P<0.001), for a change that was partly independentof weight loss alone.
Conclusions Selective CB1-receptor blockade with rimonabantsignificantly reduces body weight and waist circumference andimproves the profile of several metabolic risk factors in high-riskpatients who are overweight or obese and have an atherogenicdyslipidemia.
Source Information
From the Quebec Heart Institute, Laval Hospital Research Center, and the Division of Kinesiology, Department of Social and Preventive Medicine, Laval University, Ste.-Foy, Que., Canada (J.-P.D.); the Service of Therapeutic Education for Chronic Diseases, University Hospital Geneva, Geneva (A.G.); and the Department of Body Composition and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden (L.S.).
Address reprint requests to Dr. Després at the Quebec Heart Institute, Laval Hospital Research Center, Pavilion Marguerite-D'Youville, 4th Fl., 2725 Chemin Ste.-Foy, Ste.-Foy, QC G1V 4G5, Canada, or at jean-pierre.despres{at}crhl.ulaval.ca.
Butler, H., Korbonits, M.
(2009). Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol
161: 655-662
[Abstract][Full Text]
Flamment, M., Gueguen, N., Wetterwald, C., Simard, G., Malthiery, Y., Ducluzeau, P.-H.
(2009). Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab.
297: E1162-E1170
[Abstract][Full Text]
Esteve, E., Ricart, W., Fernandez-Real, J. M.
(2009). Adipocytokines and Insulin Resistance: The possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care
32: S362-S367
[Full Text]
Wilbur, K.
(2009). Nonviral Hepatitis. Journal of Pharmacy Practice
22: 388-404
[Abstract]
Cocco, G., Chu, D.
(2009). Rimonabant may induce atrial fibrillation. BMJ
338: b1061-b1061
[Full Text]
Bonsignore, M. R., Eckel, J.
(2009). Metabolic aspects of obstructive sleep apnoea syndrome. ERR
18: 113-124
[Abstract][Full Text]
de Kloet, A. D., Woods, S. C.
(2009). Endocannabinoids and Their Receptors as Targets for Obesity Therapy. Endocrinology
150: 2531-2536
[Abstract][Full Text]
Richey, J. M., Woolcott, O. O., Stefanovski, D., Harrison, L. N., Zheng, D., Lottati, M., Hsu, I. R., Kim, S. P., Kabir, M., Catalano, K. J., Chiu, J. D., Ionut, V., Kolka, C., Mooradian, V., Bergman, R. N.
(2009). Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs. Am. J. Physiol. Endocrinol. Metab.
296: E1311-E1318
[Abstract][Full Text]
Migrenne, S., Lacombe, A., Lefevre, A.-L., Pruniaux, M.-P., Guillot, E., Galzin, A.-M., Magnan, C.
(2009). Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol.
296: R929-R935
[Abstract][Full Text]
Mathieu, P., Poirier, P., Pibarot, P., Lemieux, I., Despres, J.-P.
(2009). Visceral Obesity: The Link Among Inflammation, Hypertension, and Cardiovascular Disease. Hypertension
53: 577-584
[Full Text]
Taskinen, M.-R.
(2009). ADAGIO-Lipids Gives Promises but Faces the Setbacks. Arterioscler. Thromb. Vasc. Bio.
29: 339-340
[Full Text]
Despres, J.-P., Ross, R., Boka, G., Almeras, N., Lemieux, I., for the ADAGIO-Lipids Investigators,
(2009). Effect of Rimonabant on the High-Triglyceride/ Low-HDL-Cholesterol Dyslipidemia, Intraabdominal Adiposity, and Liver Fat: The ADAGIO-Lipids Trial. Arterioscler. Thromb. Vasc. Bio.
29: 416-423
[Abstract][Full Text]
Jiang, L.-s., Pu, J., Han, Z.-h., Hu, L.-h., He, B.
(2009). Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res
81: 805-813
[Abstract][Full Text]
Idelevich, E., Kirch, W., Schindler, C.
(2009). Current pharmacotherapeutic concepts for the treatment of obesity in adults. Ther Adv Cardiovasc Dis
3: 75-90
[Abstract]
Van Laere, K., Goffin, K., Bormans, G., Casteels, C., Mortelmans, L., de Hoon, J., Grachev, I., Vandenbulcke, M., Pieters, G.
(2009). Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament. Arch Gen Psychiatry
66: 196-204
[Abstract][Full Text]
Watanabe, T., Kubota, N., Ohsugi, M., Kubota, T., Takamoto, I., Iwabu, M., Awazawa, M., Katsuyama, H., Hasegawa, C., Tokuyama, K., Moroi, M., Sugi, K., Yamauchi, T., Noda, T., Nagai, R., Terauchi, Y., Tobe, K., Ueki, K., Kadowaki, T.
(2009). Rimonabant Ameliorates Insulin Resistance via both Adiponectin-dependent and Adiponectin-independent Pathways. J. Biol. Chem.
284: 1803-1812
[Abstract][Full Text]
Sugamura, K., Sugiyama, S., Nozaki, T., Matsuzawa, Y., Izumiya, Y., Miyata, K., Nakayama, M., Kaikita, K., Obata, T., Takeya, M., Ogawa, H.
(2009). Activated Endocannabinoid System in Coronary Artery Disease and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on Macrophages. Circulation
119: 28-36
[Abstract][Full Text]
Elangbam, C. S.
(2009). Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns. Veterinary Pathology
46: 10-24
[Abstract][Full Text]
Pacher, P.
(2009). Cannabinoid CB1 Receptor Antagonists for Atherosclerosis and Cardiometabolic Disorders: New Hopes, Old Concerns?. Arterioscler. Thromb. Vasc. Bio.
29: 7-9
[Full Text]
Dol-Gleizes, F., Paumelle, R., Visentin, V., Mares, A.-M., Desitter, P., Hennuyer, N., Gilde, A., Staels, B., Schaeffer, P., Bono, F.
(2009). Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor-Deficient Mice. Arterioscler. Thromb. Vasc. Bio.
29: 12-18
[Abstract][Full Text]
Hajer, G. R., van Haeften, T. W., Visseren, F. L.J.
(2008). Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J
29: 2959-2971
[Abstract][Full Text]
Esposito, I., Proto, M. C., Gazzerro, P., Laezza, C., Miele, C., Alberobello, A. T., D'Esposito, V., Beguinot, F., Formisano, P., Bifulco, M.
(2008). The Cannabinoid CB1 Receptor Antagonist Rimonabant Stimulates 2-Deoxyglucose Uptake in Skeletal Muscle Cells by Regulating the Expression of Phosphatidylinositol-3-kinase. Mol. Pharmacol.
74: 1678-1686
[Abstract][Full Text]
Kunos, G., Osei-Hyiaman, D., Liu, J., Godlewski, G., Batkai, S.
(2008). Endocannabinoids and the Control of Energy Homeostasis. J. Biol. Chem.
283: 33021-33025
[Abstract][Full Text]
Fioravanti, B., De Felice, M., Stucky, C. L., Medler, K. A., Luo, M.-C., Gardell, L. R., Ibrahim, M., Malan, T. P. Jr, Yamamura, H. I., Ossipov, M. H., King, T., Lai, J., Porreca, F., Vanderah, T. W.
(2008). Constitutive Activity at the Cannabinoid CB1 Receptor Is Required for Behavioral Response to Noxious Chemical Stimulation of TRPV1: Antinociceptive Actions of CB1 Inverse Agonists. J. Neurosci.
28: 11593-11602
[Abstract][Full Text]
Fruchart, J.-C., Sacks, F. M, Hermans, M. P, Assmann, G., Brown, W V., Ceska, R., Chapman, M J., Dodson, P. M, Fioretto, P., Ginsberg, H. N, Kadowaki, T., Lablanche, J.-M., Marx, N., Plutzky, J., Reiner, Z., Rosenson, R. S, Staels, B., Stock, J. K, Sy, R., Wanner, C., Zambon, A., Zimmet, P.
(2008). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabetes and Vascular Disease Research
5: 319-335
[Abstract]
Nogueiras, R., Veyrat-Durebex, C., Suchanek, P. M., Klein, M., Tschop, J., Caldwell, C., Woods, S. C., Wittmann, G., Watanabe, M., Liposits, Z., Fekete, C., Reizes, O., Rohner-Jeanrenaud, F., Tschop, M. H.
(2008). Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats. Diabetes
57: 2977-2991
[Abstract][Full Text]
Bray, G. A.
(2008). Lifestyle and Pharmacological Approaches to Weight Loss: Efficacy and Safety. J. Clin. Endocrinol. Metab.
93: s81-s88
[Abstract][Full Text]
Bakhai, A.
(2008). Adipokines--targeting a root cause of cardiometabolic risk. QJM
101: 767-776
[Abstract][Full Text]
Ramaraj, R, Chellappa, P
(2008). Cardiovascular risk in South Asians. Postgrad. Med. J.
84: 518-523
[Abstract][Full Text]
Srinivasan, B T, Jarvis, J, Khunti, K, Davies, M J
(2008). Recent advances in the management of type 2 diabetes mellitus: a review. Postgrad. Med. J.
84: 524-531
[Abstract][Full Text]
Pacher, P., Mukhopadhyay, P., Mohanraj, R., Godlewski, G., Batkai, S., Kunos, G.
(2008). Modulation of the Endocannabinoid System in Cardiovascular Disease: Therapeutic Potential and Limitations. Hypertension
52: 601-607
[Full Text]
Ruby, M. A., Nomura, D. K., Hudak, C. S. S., Mangravite, L. M., Chiu, S., Casida, J. E., Krauss, R. M.
(2008). Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc. Natl. Acad. Sci. USA
105: 14561-14566
[Abstract][Full Text]
Izzo, A A, Camilleri, M
(2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut
57: 1140-1155
[Abstract][Full Text]
Andrikopoulos, G. K., Tzeis, S.
(2008). Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism. ANGIOLOGY
59: 44S-48S
[Abstract]
Van Gaal, L. F., Scheen, A. J., Rissanen, A. M., Rossner, S., Hanotin, C., Ziegler, O., for the RIO-Europe Study Group,
(2008). Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur Heart J
29: 1761-1771
[Abstract][Full Text]
Kintscher, U.
(2008). The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. Eur Heart J
29: 1709-1710
[Full Text]
Wilding, J., Finer, N.
(2008). Weight management and cardiovascular disease: implications of recent and ongoing clinical trials. British Journal of Diabetes & Vascular Disease
8: 170-176
[Abstract]
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., Boren, J.
(2008). Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Arterioscler. Thromb. Vasc. Bio.
28: 1225-1236
[Abstract][Full Text]
Benzinou, M., Chevre, J.-C., Ward, K. J., Lecoeur, C., Dina, C., Lobbens, S., Durand, E., Delplanque, J., Horber, F. F., Heude, B., Balkau, B., Borch-Johnsen, K., Jorgensen, T., Hansen, T., Pedersen, O., Meyre, D., Froguel, P.
(2008). Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet
17: 1916-1921
[Abstract][Full Text]
Herling, A. W., Kilp, S., Elvert, R., Haschke, G., Kramer, W.
(2008). Increased Energy Expenditure Contributes More to the Body Weight-Reducing Effect of Rimonabant than Reduced Food Intake in Candy-Fed Wistar Rats. Endocrinology
149: 2557-2566
[Abstract][Full Text]
Nissen, S. E., Nicholls, S. J., Wolski, K., Rodes-Cabau, J., Cannon, C. P., Deanfield, J. E., Despres, J.-P., Kastelein, J. J. P., Steinhubl, S. R., Kapadia, S., Yasin, M., Ruzyllo, W., Gaudin, C., Job, B., Hu, B., Bhatt, D. L., Lincoff, A. M., Tuzcu, E. M., for the STRADIVARIUS Investigators,
(2008). Effect of Rimonabant on Progression of Atherosclerosis in Patients With Abdominal Obesity and Coronary Artery Disease: The STRADIVARIUS Randomized Controlled Trial. JAMA
299: 1547-1560
[Abstract][Full Text]
Rumsfeld, J. S., Nallamothu, B. K.
(2008). The Hope and Fear of Rimonabant. JAMA
299: 1601-1602
[Full Text]
Bloom, S. R., Kuhajda, F. P., Laher, I., Pi-Sunyer, X., Ronnett, G. V., Tan, T. M.M., Weigle, D. S.
(2008). The Obesity Epidemic: Pharmacological Challenges. Mol. Interv.
8: 82-98
[Abstract][Full Text]
Horvath, K., Jeitler, K., Siering, U., Stich, A. K., Skipka, G., Gratzer, T. W., Siebenhofer, A.
(2008). Long-term Effects of Weight-Reducing Interventions in Hypertensive Patients: Systematic Review and Meta-analysis. Arch Intern Med
168: 571-580
[Abstract][Full Text]
Barnett, A. H
(2008). The importance of treating cardiometabolic risk factors in patients with type 2 diabetes. Diabetes and Vascular Disease Research
5: 9-14
[Abstract]
Ferns, G., Keti, V.
(2008). HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem
45: 122-128
[Abstract][Full Text]
Despres, J.-P., Brewer, H. B.
(2008). Metabolic syndrome: the dysmetabolic state of dysfunctional adipose tissue and insulin resistance. Eur Heart J Suppl
10: B1-B3
[Full Text]
Despres, J.-P., Poirier, P., Bergeron, J., Tremblay, A., Lemieux, I., Almeras, N.
(2008). From individual risk factors and the metabolic syndrome to global cardiometabolic risk. Eur Heart J Suppl
10: B24-B33
[Abstract][Full Text]
Nesto, R. W., Mackie, K.
(2008). Endocannabinoid system and its implications for obesity and cardiometabolic risk. Eur Heart J Suppl
10: B34-B41
[Abstract][Full Text]
(2008). Needs Assessment. The Diabetes Educator
34: 30S-31S
[Full Text]
Boyd, S. T.
(2008). Management Through Risk Factor Modification. The Diabetes Educator
34: 42S-48S
[Abstract][Full Text]
Munoz-Luque, J., Ros, J., Fernandez-Varo, G., Tugues, S., Morales-Ruiz, M., Alvarez, C. E., Friedman, S. L., Arroyo, V., Jimenez, W.
(2008). Regression of Fibrosis after Chronic Stimulation of Cannabinoid CB2 Receptor in Cirrhotic Rats. J. Pharmacol. Exp. Ther.
324: 475-483
[Abstract][Full Text]
Siegmund, S. V., Schwabe, R. F.
(2008). Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol.
294: G357-G362
[Abstract][Full Text]
Bianchi, C., Miccoli, R., Penno, G., Del Prato, S.
(2008). Primary Prevention of Cardiovascular Disease in People With Dysglycemia. Diabetes Care
31: S208-S214
[Abstract][Full Text]
Van Gaal, L., Pi-Sunyer, X., Despres, J.-P., McCarthy, C., Scheen, A.
(2008). Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care
31: S229-S240
[Abstract][Full Text]
Nilsson, P. M.
(2008). Is Weight Loss Beneficial for Reduction of Morbidity and Mortality?: What is the controversy about?. Diabetes Care
31: S278-S283
[Abstract][Full Text]
Giugliano, D., Ceriello, A., Esposito, K.
(2008). Are there specific treatments for the metabolic syndrome?. Am. J. Clin. Nutr.
87: 8-11
[Abstract][Full Text]
Pagano, C., Pilon, C., Calcagno, A., Urbanet, R., Rossato, M., Milan, G., Bianchi, K., Rizzuto, R., Bernante, P., Federspil, G., Vettor, R.
(2007). The Endogenous Cannabinoid System Stimulates Glucose Uptake in Human Fat Cells via Phosphatidylinositol 3-Kinase and Calcium-Dependent Mechanisms. J. Clin. Endocrinol. Metab.
92: 4810-4819
[Abstract][Full Text]
Chambers, A. P., Vemuri, V. K., Peng, Y., Wood, J. T., Olszewska, T., Pittman, Q. J., Makriyannis, A., Sharkey, K. A.
(2007). A neutral CB1 receptor antagonist reduces weight gain in rat. Am. J. Physiol. Regul. Integr. Comp. Physiol.
293: R2185-R2193
[Abstract][Full Text]
Barnett, A. H
(2007). Review: Pharmacotherapy as part of a weight management programme: a UK perspective. British Journal of Diabetes & Vascular Disease
7: 268-277
[Abstract]
Schindler, C.
(2007). Review: The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis?. Ther Adv Cardiovasc Dis
1: 7-26
[Abstract]
Dunican, K. C., Desilets, A. R., DeBellis, R. J.
(2007). State of the Art Review: Long-term Pharmacotherapy for Overweight and Obesity: A Review of Sibutramine, Orlistat, and Rimonabant. AMERICAN JOURNAL OF LIFESTYLE MEDICINE
1: 367-388
[Abstract]
Echahidi, N., Mohty, D., Pibarot, P., Despres, J.-P., O'Hara, G., Champagne, J., Philippon, F., Daleau, P., Voisine, P., Mathieu, P.
(2007). Obesity and Metabolic Syndrome Are Independent Risk Factors for Atrial Fibrillation After Coronary Artery Bypass Graft Surgery. Circulation
116: I-213-I-219
[Abstract][Full Text]
Herling, A. W., Gossel, M., Haschke, G., Stengelin, S., Kuhlmann, J., Muller, G., Schmoll, D., Kramer, W.
(2007). CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am. J. Physiol. Endocrinol. Metab.
293: E826-E832
[Abstract][Full Text]
Echahidi, N., Pibarot, P., Despres, J.-P., Daigle, J.-M., Mohty, D., Voisine, P., Baillot, R., Mathieu, P.
(2007). Metabolic Syndrome Increases Operative Mortality in Patients Undergoing Coronary Artery Bypass Grafting Surgery. J Am Coll Cardiol
50: 843-851
[Abstract][Full Text]
Singh, I. M., Shishehbor, M. H., Ansell, B. J.
(2007). High-Density Lipoprotein as a Therapeutic Target: A Systematic Review. JAMA
298: 786-798
[Abstract][Full Text]
Garwood, C. L., Potts, L. A.
(2007). Emerging pharmacotherapies for smoking cessation. Am J Health Syst Pharm
64: 1693-1698
[Abstract][Full Text]
Mukhopadhyay, P., Batkai, S., Rajesh, M., Czifra, N., Harvey-White, J., Hasko, G., Zsengeller, Z., Gerard, N. P., Liaudet, L., Kunos, G., Pacher, P.
(2007). Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity. J Am Coll Cardiol
50: 528-536
[Abstract][Full Text]
Authors/Task Force Members:, , Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Narkiewicz, K., Ruilope, L., Rynkiewicz, A., Schmieder, R. E., Struijker Boudier, H. A.J., Zanchetti, A., ESC Committee for Practice Guidelines (CPG):, , Vahanian, A., Camm, J., De Caterina, R., Dean, V., Dickstein, K., Filippatos, G., Funck-Brentano, C., Hellemans, I., Kristensen, S. D., McGregor, K., Sechtem, U., Silber, S., Tendera, M., Widimsky, P., Zamorano, J. L., ESH Scientific Council:, , Kjeldsen, S. E., Erdine, S., Narkiewicz, K., Kiowski, W., Agabiti-Rosei, E., Ambrosioni, E., Cifkova, R., Dominiczak, A., Fagard, R., Heagerty, A. M., Laurent, S., Lindholm, L. H., Mancia, G., Manolis, A., Nilsson, P. M., Redon, J., Schmieder, R. E., Struijker-Boudier, H. A.J., Viigimaa, M., Document Reviewers:, , Filippatos, G., Adamopoulos, S., Agabiti-Rosei, E., Ambrosioni, E., Bertomeu, V., Clement, D., Erdine, S., Farsang, C., Gaita, D., Kiowski, W., Lip, G., Mallion, J.-M., Manolis, A. J., Nilsson, P. M., O'Brien, E., Ponikowski, P., Redon, J., Ruschitzka, F., Tamargo, J., van Zwieten, P., Viigimaa, M., Waeber, B., Williams, B., Zamorano, J. L.
(2007). 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J
0: ehm236v1-75
[Full Text]
(2007). Less weight or more hype with {blacktriangledown}rimonabant?. DTB
45: 41-44
[Abstract][Full Text]
Bray, G. A., Greenway, F. L.
(2007). Pharmacological Treatment of the Overweight Patient. Pharmacol. Rev.
59: 151-184
[Full Text]
Russo, P., Strazzullo, P., Cappuccio, F. P., Tregouet, D. A., Lauria, F., Loguercio, M., Barba, G., Versiero, M., Siani, A.
(2007). Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men. J. Clin. Endocrinol. Metab.
92: 2382-2386
[Abstract][Full Text]
Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S., Santoro, A.
(2007). Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects. Mol. Pharmacol.
71: 1445-1456
[Abstract][Full Text]
Wannamethee, S. G., Lowe, G. D.O., Rumley, A., Cherry, L., Whincup, P. H., Sattar, N.
(2007). Adipokines and Risk of Type 2 Diabetes in Older Men. Diabetes Care
30: 1200-1205
[Abstract][Full Text]
Kakafika, A. I., Mikhailidis, D. P., Karagiannis, A., Athyros, V. G.
(2007). The Role of Endocannabinoid System Blockade in the Treatment of the Metabolic Syndrome. J Clin Pharmacol
47: 642-652
[Abstract][Full Text]
Yuan, G., Al-Shali, K. Z., Hegele, R. A.
(2007). Hypertriglyceridemia: its etiology, effects and treatment. CMAJ
176: 1113-1120
[Abstract][Full Text]
Wiecek, A., Adamczak, M., Chudek, J.
(2007). Adiponectin--an adipokine with unique metabolic properties. Nephrol Dial Transplant
22: 981-988
[Full Text]
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grubler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., Pagotto, U.
(2007). Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function. Endocrinology
148: 1574-1581
[Abstract][Full Text]
Lillo, J. L.
(2007). The Endocannabinoid System as a Novel Approach for Managing Obesity. JAOA: Journal of the American Osteopathic Association
107: S12-S20
[Abstract][Full Text]
Freeman, J. S.
(2007). Reducing the "Domino Effect" of the Metabolic Syndrome. JAOA: Journal of the American Osteopathic Association
107: Cov2-S3
[Full Text]
Szmitko, P. E., Teoh, H., Stewart, D. J., Verma, S.
(2007). Adiponectin and cardiovascular disease: state of the art?. Am. J. Physiol. Heart Circ. Physiol.
292: H1655-H1663
[Abstract][Full Text]
Patel, P. N., Pathak, R.
(2007). Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm
64: 481-489
[Abstract][Full Text]
Demerath, E. W, Shen, W., Lee, M., Choh, A. C, Czerwinski, S. A, Siervogel, R. M, Towne, B.
(2007). Approximation of total visceral adipose tissue with a single magnetic resonance image. Am. J. Clin. Nutr.
85: 362-368
[Abstract][Full Text]
Fujioka, K., Lee, M. W.
(2007). Pharmacologic Treatment Options for Obesity: Current and Potential Medications. Nutr Clin Pract
22: 50-54
[Abstract][Full Text]
Freemark, M.
(2007). Pharmacotherapy of Childhood Obesity: An evidence-based, conceptual approach. Diabetes Care
30: 395-402
[Full Text]
Opie, L. H.
(2007). Metabolic Syndrome. Circulation
115: e32-e35
[Full Text]
Previous
